2/5
07:01 am
bcrx
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
Medium
Report
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
2/5
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/30
10:38 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
1/24
04:36 pm
bcrx
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus [Yahoo! Finance]
Low
Report
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus [Yahoo! Finance]
1/23
09:00 am
bcrx
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
Low
Report
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
1/22
02:36 pm
bcrx
BioCryst: The $700 Million Pivot From Oral Convenience To Injectable [Seeking Alpha]
Low
Report
BioCryst: The $700 Million Pivot From Oral Convenience To Injectable [Seeking Alpha]
1/21
04:22 pm
bcrx
Astria Stockholders Vote to Approve Acquisition by BioCryst [Yahoo! Finance]
Low
Report
Astria Stockholders Vote to Approve Acquisition by BioCryst [Yahoo! Finance]
1/12
08:55 am
bcrx
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range [Yahoo! Finance]
Medium
Report
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range [Yahoo! Finance]
1/12
07:00 am
bcrx
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
Medium
Report
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
1/9
06:11 am
bcrx
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction [Yahoo! Finance]
Low
Report
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction [Yahoo! Finance]
1/6
08:17 am
bcrx
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/6
07:01 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/6
07:00 am
bcrx
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
12/21
10:19 am
bcrx
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 [Yahoo! Finance]
Low
Report
H.C. Wainwright Lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 From $30 [Yahoo! Finance]
12/15
08:27 pm
bcrx
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]
Low
Report
Does The Market Misread BioCryst Pharmaceuticals After DCF Upside And Low Sales Multiple In 2025? [Yahoo! Finance]
12/15
11:02 am
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by analysts at HC Wainwright from $30.00 to $32.00. They now have a "buy" rating on the stock.
12/12
07:39 am
bcrx
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]
Medium
Report
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years [Yahoo! Finance]
12/12
07:00 am
bcrx
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
Low
Report
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
12/4
07:00 am
bcrx
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3
04:28 pm
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/3
10:37 am
bcrx
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]
Medium
Report
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update [Yahoo! Finance]
12/3
07:00 am
bcrx
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
Medium
Report
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
11/30
12:37 am
bcrx
BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers [Yahoo! Finance]
Low
Report
BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers [Yahoo! Finance]
11/27
02:45 pm
bcrx
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.